LDCT screening is a low-dose computed tomography scan designed to detect lung cancer early, before symptoms appear. It uses roughly 75% less radiation than a standard chest CT and takes only a few minutes. In the largest clinical trial to date, annual LDCT screening reduced lung cancer deaths by 20% among high-risk adults, making it the only proven screening method for the disease.
How LDCT Differs From a Standard CT Scan
A standard chest CT delivers about 8 millisieverts (mSv) of radiation. An LDCT scan delivers around 1.5 to 2 mSv, which is closer to a mammogram than a traditional CT. To put that in perspective, the average American absorbs about 3 mSv per year just from natural background radiation. The lower dose is achieved by reducing the electrical current that powers the X-ray tube, which produces a slightly grainier image but still captures enough detail to spot small lung nodules.
Modern LDCT scanners use multiple rows of detectors and reconstruct images in slices as thin as 1 to 1.25 millimeters. That thinness matters because most nodules found during screening are small. Thin slices let radiologists measure nodule volume precisely and allow software to flag suspicious spots automatically. Newer reconstruction techniques further sharpen image quality without adding radiation, so the technology continues to improve even as the dose stays low.
Who Qualifies for Screening
The U.S. Preventive Services Task Force recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and either currently smoke or quit within the past 15 years. A “pack-year” means smoking one pack (20 cigarettes) per day for one year. So someone who smoked two packs a day for 10 years has the same 20 pack-year history as someone who smoked one pack a day for 20 years.
Screening is meant to stop once a person has gone 15 years without smoking or develops a health condition that would seriously limit life expectancy or make lung surgery impractical. Medicare covers the screening with no out-of-pocket cost for people who meet these criteria, though it requires an initial visit with a provider to discuss the benefits and risks before the first scan. Most private insurers follow the same guidelines.
What the Scan Is Like
You lie on your back on a narrow table that slides into a doughnut-shaped scanner. No IV contrast, no fasting, and no sedation. You hold your breath for a few seconds while the machine captures images of your entire chest. The scan itself is painless and typically finished in under a minute, though the whole appointment, including check-in and positioning, usually takes about 15 to 30 minutes.
How Results Are Reported
Radiologists score LDCT results using a standardized system called Lung-RADS, which assigns your scan a category from 1 to 4.
- Category 1 (Negative): No lung nodules found. You return for your next annual screening in 12 months.
- Category 2 (Benign): A nodule was found, but its appearance or slow growth pattern suggests it is not cancerous. You return in 12 months.
- Category 3 (Probably Benign): A nodule needs a closer look. You come back for a follow-up LDCT in 6 months to check whether it has changed.
- Category 4A (Suspicious): A nodule has features that raise concern. A repeat LDCT in 3 months is typical, and a PET scan may be considered for larger nodules.
- Category 4B (Very Suspicious): A nodule looks highly concerning. You are referred for further evaluation, which may include a diagnostic CT, PET scan, or tissue biopsy.
Most people fall into categories 1 or 2, meaning no immediate action beyond continuing annual screening.
How Well It Works
The strongest evidence comes from the National Lung Screening Trial (NLST), which enrolled over 53,000 people and found a 20% reduction in lung cancer deaths among those screened with LDCT compared to those screened with chest X-rays. The Dutch-Belgian NELSON trial confirmed a similar reduction. A UK trial using even a single LDCT scan showed a comparable drop in lung cancer mortality. These results are consistent: catching lung cancer at an earlier stage, when it can still be surgically removed, saves lives.
Without screening, about 75% of lung cancers are diagnosed at an advanced stage. LDCT shifts that balance by detecting tumors when they are still small and localized, which dramatically improves the odds of successful treatment.
False Positives and Overdiagnosis
The most common downside of LDCT is a false positive, where the scan flags something that turns out not to be cancer. In the NLST, roughly 25% of scans in the first two rounds were classified as positive, and the vast majority of those were ultimately benign. Many false positives are resolved with a simple follow-up scan a few months later, but some lead to more invasive steps like biopsies, which carry their own small risks.
Overdiagnosis is a separate concern. This means detecting a cancer that is real but so slow-growing that it would never have caused symptoms or death in a person’s lifetime. Estimates vary widely. The NLST put overdiagnosis at roughly 18.5% of screen-detected cancers, while a Danish trial estimated it could be as high as 67%. The true number likely falls somewhere in between and depends on the population being screened, their age, and other health factors. Overdiagnosis can lead to unnecessary treatment, including surgery, radiation, or chemotherapy for a tumor that posed little threat.
Radiation Risk Over Time
Each individual LDCT scan delivers a small dose of radiation, but screening is annual. Over a decade of screening, those doses accumulate. Some follow-up scans for suspicious nodules may use standard-dose CT, which adds more. In studies that tracked total radiation exposure from screening plus follow-up procedures, the average yearly dose ranged from 0.9 to 1.7 mSv per person. For the eligible population (people at high risk of lung cancer due to smoking), the mortality benefit of finding cancer early significantly outweighs the small theoretical cancer risk from cumulative radiation exposure.
Finding a Screening Center
Not every imaging facility is set up for lung cancer screening. The American College of Radiology (ACR) designates specific centers that meet its standards, which include using CT scanners accredited for chest imaging, keeping radiation doses below established thresholds, employing radiologists who have interpreted at least 200 chest CT cases in the prior three years, and reporting results using the Lung-RADS system. These designated centers also participate in a national registry that tracks screening outcomes. You can search for an ACR-designated lung cancer screening center on the ACR’s website by entering your zip code.